Novo Nordisk Changes Plans for Kidney Disease Drug
Novo Nordisk halts more tests for its kidney disease medicine, ziltivekimab, impacting its potential for big sales.
A promising new medicine for kidney disease faces challenges. Novo Nordisk, a major drug company, stopped two more large studies for its drug, ziltivekimab. This news changes the future for the medicine.
Experts once thought ziltivekimab could earn billions of dollars. The drug aims to help people with chronic kidney disease (CKD). It works by lowering inflammation, a key issue in CKD. Now, the path for this drug looks less certain.
Novo Nordisk decided to stop these trials. This move affects the drug's journey to market. Companies need successful large trials for new medicines to be approved. This allows the drug to help many patients. Novo Nordisk continues to test ziltivekimab in other studies. The company is learning more about the drug. They are finding the best ways to use it.
For patients with chronic kidney disease, new treatments are always important. This news means a specific path for one drug is changing. We will watch for more updates from Novo Nordisk. New medicines still come to help people. Companies keep working for better health.
Source: FierceBiotech
More from Biotech
